Showing results (181-190 of 495) with videos related to
Sort By:
Pageof 50
Health Services Research|February 23, 2023
Market dynamics of authorized generics in Medicaid from 2014 to 2020Benjamin N Rome, Simon J Gunter, Aaron S KesselheimHealth Services Research|July 14, 2025
Share of Sales Subject to Medicare Inflation Rebates and Price Increases of Top-Selling DrugsAlexander C Egilman, Aaron S Kesselheim, Benjamin N RomeThe Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|May 31, 2024
Medicare Should Cover Weight Loss Drugs as Long as the Prices are AffordableCatherine S Hwang, Aaron S Kesselheim, Benjamin N RomeClinical Pharmacology and Therapeutics|October 13, 2022
Patient Out-of-Pocket Costs Following the Availability of Biosimilar Versions of InfliximabKimberly Feng, Aaron S Kesselheim, Massimiliano Russo, et al.Frontiers in Pharmacology|October 5, 2020
Getting the Right Evidence After Drug ApprovalRick A Vreman, Hubert G M Leufkens, Aaron S KesselheimBMJ (Clinical Research Ed.)|July 19, 2019
Spending on World Health Organization essential medicines in Medicare Part D, 2011-15: retrospective cost analysisDavid G Li, Mehdi Najafzadeh, Aaron S Kesselheim, et al.Plos Medicine|March 18, 2015
Paying physicians to prescribe generic drugs and follow-on biologics in the United StatesAmeet Sarpatwari, Niteesh K Choudhry, Jerry Avorn, et al.JAMA Network Open|November 8, 2022
Variations in Use of Diabetes Drugs With Cardiovascular Benefits Among Medicaid PatientsMike Z Zhai, Jerry Avorn, Jun Liu, et al.Journal of Managed Care & Specialty Pharmacy|December 23, 2023
Administrative action on drug pricing: Lessons and opportunities for the Center for Medicare and Medicaid InnovationIan T T Liu, Hussain S Lalani, Aaron S KesselheimHealth Services Research|December 20, 2022
Alternatives to the quality-adjusted life year: How well do they address common criticisms?Leah Z Rand, G J Melendez-Torres, Aaron S KesselheimPageof 50